The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|November 2, 2011
- Pharmaceutical Technology-11-02-2011
- Volume 35
- Issue 11
Pharmaceutical Technology, November 2011 Issue (PDF)
Click the title above to open the Pharmaceutical Technology November 2011 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 15 years ago
Growth for Small Pharmaalmost 15 years ago
Drug Shortages Create Crisis for Manufacturers, Regulatorsalmost 15 years ago
Using Simulation to Improve Drug-Delivery Effectivenessalmost 15 years ago
Easy on the Alcohol!almost 15 years ago
Catalyzing the Synthesisalmost 15 years ago
Super Fast Pharmaalmost 15 years ago
Global Healthcare on the Ground: Novartis Focuses on Treating Rare Diseasesalmost 15 years ago
Managing the Global Clinical-Trial Material Supply Chainalmost 15 years ago
In the Spotlight November 2011almost 15 years ago
Biosimilars' Technology NeedsAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement